EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ex vivo and in vivo HIV-1 latency reversal by “Mukungulu,” a protein kinase C-activating African medicinal plant extract

Khumoekae Richard, Zhe Yuan, Hsin-Yao Tang, Aaron R Goldman, Riza Kuthu, Boingotlo Raphane, Emery T Register, Paridhima Sharma, Brian N Ross, Jessicamarie Morris, David E Williams, Carol Cheney und 9 weitere

mBio · 2025

DOI: 10.1128/mbio.03816-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2025. Verfasst von Khumoekae Richard und 20 weiteren Autor:innen. Beteiligte Einrichtung: The Wistar Institute, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Virus Latency, HIV-1, Plant Extracts, HIV Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, CIHR, NIH Cancer Center Support Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New HIV latency-reversing agents (LRAs) are needed that can reactivate and/or eliminate HIV reservoirs. “Mukungulu,” prepared from the plant Croton megalobotrys Müll Arg., is traditionally used for HIV/AIDS management in northern Botswana despite an abundance of protein kinase C-activating phorbol esters (“namushens”). Here, we show that Mukungulu is tolerated in mice at up to 12.5 mg/kg while robustly reversing latency in antiretroviral therapy (ART)-suppressed HIV-infected humanized mice at 5 mg/kg. In primary cells from ART-suppressed people living with HIV-1, 1 µg/mL Mukungulu reverses latency at levels similar to or superior to anti-CD3/CD28 positive control, based on HIV gag-p24 protein expression, while the magnitude of HIV reactivation in peripheral blood mononuclear cells corresponds to intact proviral burden in CD4+ T-cells. Bioassay-guided fractionation identifies five namushen phorbol esters that can reactivate HIV, but when combined, they do not match Mukungulu’s activity, suggesting the presence of additional enhancing factors. Together, these results identify Mukungulu as a robust natural LRA that is already in use by humans and which may warrant inclusion in future HIV cure and ART-free remission efforts. IMPORTANCE Current HIV therapies do not act on the latent viral reservoir, which is the major obstacle toward achieving a drug-free HIV remission and/or an HIV cure. “Mukungulu,” a bark preparation from Croton megalobotrys Müll Arg., has been documented for its traditional use for HIV/AIDS management in northern Botswana. Here, we show that Mukungulu activates viral reservoirs, a key step toward identifying and potentially eliminating these reservoirs, in both cells from people living with HIV as well as in HIV-infected humanized mice. The majority of this activity is due to the abundance of five phorbol esters (“namushens”). This reverse pharmacology-based approach has therefore identified a potent activator of viral reservoirs that is already traditionally used by humans, which in turn can inform and advance western HIV cure and drug-free remission efforts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Virus LatencyHIV-1Plant ExtractsHIV InfectionsPlants, MedicinalProtein Kinase CCrotonAnti-HIV AgentsHumansAnimalsMiceVirus ActivationPhorbol EstersBotswanaCD4-Positive T-LymphocytesLeukocytes, MononuclearFemale

Stichwörter der Autor:innen

HIVex vivohumanized micelatency reversalnatural productstraditional medicines

Substanzen

Plant ExtractsPhorbol EstersProtein Kinase CAnti-HIV Agents

Autor:innen und Institutionen

  • The Wistar Institute, Philadelphia, Pennsylvania, USA.
  • University of Botswana, Gaborone, Botswana.
  • Departments of Chemistry and Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Merck and Co Inc, Rahway, New Jersey, USA.
  • Jonathan Lax Immune Disorders Treatment Center, Philadelphia Field Initiating Group for HIV-1 Trials, Philadelphia, Pennsylvania, USA.
  • AccelevirDx, Baltimore, Maryland, USA.

ORCID-Profile: Ian Tietjen, Luis J Montaner

Förderung

  • NIAID NIH HHS
  • CIHR
  • NIH Cancer Center Support Grant
  • Robert I Jacobs Fund of The Philadelphia Foundation
  • W. W. Smith Charitable Trust
  • NIH HHS
  • Sub-Saharan African Network for TB/HIV Research Excellence
  • NCI NIH HHS

Zitieren

APA

Richard, K., Yuan, Z., Tang, H. Y., Goldman, A. R., Kuthu, R., Raphane, B., Register, E. T., Sharma, P., Ross, B. N., Morris, J., Williams, D. E., Cheney, C., Wu, G., Mounzer, K., Laird, G. M., Zuck, P., Andersen, R. J., Simonambango, S., Andrae-Marobela, K., …, & Montaner, L. J. (2025). Ex vivo and in vivo HIV-1 latency reversal by “Mukungulu,” a protein kinase C-activating African medicinal plant extract. mBio. https://doi.org/10.1128/mbio.03816-24

Vancouver

Richard K, Yuan Z, Tang HY, Goldman AR, Kuthu R, Raphane B, et al. Ex vivo and in vivo HIV-1 latency reversal by “Mukungulu,” a protein kinase C-activating African medicinal plant extract. mBio. 2025. doi:10.1128/mbio.03816-24

BibTeX
@article{Richard2025,
  author = {Richard, Khumoekae and Yuan, Zhe and Tang, Hsin-Yao and Goldman, Aaron R and Kuthu, Riza and Raphane, Boingotlo and Register, Emery T and Sharma, Paridhima and Ross, Brian N and Morris, Jessicamarie and Williams, David E and Cheney, Carol and Wu, Guoxin and Mounzer, Karam and Laird, Gregory M and Zuck, Paul and Andersen, Raymond J and Simonambango, Sundana and Andrae-Marobela, Kerstin and Tietjen, Ian and Montaner, Luis J},
  title = {Ex vivo and in vivo HIV-1 latency reversal by “Mukungulu,” a protein kinase C-activating African medicinal plant extract},
  journal = {mBio},
  year = {2025},
  doi = {10.1128/mbio.03816-24}
}
Kostenlos starten →